BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10807772)

  • 1. Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection.
    Davis BM; Koç ON; Gerson SL
    Blood; 2000 May; 95(10):3078-84. PubMed ID: 10807772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
    Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
    Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
    Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
    Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
    Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU.
    Lee K; Gerson SL; Maitra B; Koç ON
    J Hematother Stem Cell Res; 2001 Oct; 10(5):691-701. PubMed ID: 11672516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.
    Zielske SP; Reese JS; Lingas KT; Donze JR; Gerson SL
    J Clin Invest; 2003 Nov; 112(10):1561-70. PubMed ID: 14617757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human long-term culture initiating cells are sensitive to benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and protected after mutant (G156A) methylguanine methyltransferase gene transfer.
    Koç ON; Reese JS; Szekely EM; Gerson SL
    Cancer Gene Ther; 1999; 6(4):340-8. PubMed ID: 10419052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
    Reese JS; Davis BM; Liu L; Gerson SL
    Clin Cancer Res; 1999 Jan; 5(1):163-9. PubMed ID: 9918215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.
    Bowman JE; Reese JS; Lingas KT; Gerson SL
    Mol Ther; 2003 Jul; 8(1):42-50. PubMed ID: 12842427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary and secondary recipients.
    Davis BM; Reese JS; Lingas K; Gerson SL
    J Hematother Stem Cell Res; 2003 Aug; 12(4):375-87. PubMed ID: 12965075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.
    Davis BM; Roth JC; Liu L; Xu-Welliver M; Pegg AE; Gerson SL
    Hum Gene Ther; 1999 Nov; 10(17):2769-78. PubMed ID: 10584923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
    Kreklau EL; Pollok KE; Bailey BJ; Liu N; Hartwell JR; Williams DA; Erickson LC
    Mol Cancer Ther; 2003 Dec; 2(12):1321-9. PubMed ID: 14707273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment.
    Maze R; Kurpad C; Pegg AE; Erickson LC; Williams DA
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1467-74. PubMed ID: 10454526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
    Fontes AM; Davis BM; Encell LP; Lingas K; Covas DT; Zago MA; Loeb LA; Pegg AE; Gerson SL
    Mol Cancer Ther; 2006 Jan; 5(1):121-8. PubMed ID: 16432170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear-localizing O6-benzylguanine-resistant GFP-MGMT fusion protein as a novel in vivo selection marker.
    Choi U; DeRavin SS; Yamashita K; Whiting-Theobald N; Linton GF; Loktionova NA; Pegg AE; Malech HL
    Exp Hematol; 2004 Aug; 32(8):709-19. PubMed ID: 15308322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication.
    Davis BM; Humeau L; Dropulic B
    Mol Ther; 2004 Feb; 9(2):160-72. PubMed ID: 14759800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of hematopoietic cells against combined O6-benzylguanine and chloroethylnitrosourea treatment by mutant forms of O6-methylguanine DNA methyltransferase.
    Williams DA; Maze R; Kurpad C; Pegg A; Erickson LC
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S105-9. PubMed ID: 10933201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro.
    Zielske SP; Gerson SL
    Mol Ther; 2002 Apr; 5(4):381-7. PubMed ID: 11945064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
    Jansen M; Sorg UR; Ragg S; Flasshove M; Seeber S; Williams DA; Moritz T
    Cancer Gene Ther; 2002 Sep; 9(9):737-46. PubMed ID: 12189523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression.
    Ball CR; Pilz IH; Schmidt M; Fessler S; Williams DA; von Kalle C; Glimm H
    Blood; 2007 Sep; 110(6):1779-87. PubMed ID: 17496202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.